Bernard serves as the chief technology officer at Mariana Oncology. Prior to joining Mariana Oncology, Bernard was president and chief operating officer of Telix Pharmaceuticals’ US business. In this role, he led regulatory and commercial operations for its clinical-stage and marketed products in renal, prostate, and brain cancer, and led the US team to the FDA approval of the prostate imaging radiopharmaceutical Illuccix®. Prior to this, he was vice president, CMC and radiopharmaceutical development, at Zevacor Pharma, Zevacor Molecular, and IBA Molecular. Bernard brings more than 20 years of experience in all phases of both small molecule and antibody based-radiopharmaceutical drug development, from the earliest stages of discovery through to New Drug Application (NDA) and commercial launches. Bernard received his PhD in chemistry from the University of Liège.